At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 enrolled
Drug / intervention
Losmapimod oral tablet +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)
In Brief
A Phase 2 clinical trial evaluating Losmapimod oral tablet and Placebo oral tablet for Facioscapulohumeral Muscular Dystrophy (FSHD). Completed, enrolled 80 participants across 17 sites in 4 countries.
Detailed Summary
This is a study to evaluate the safety and efficacy of Losmapimod in treating patients with Facioscapulohumeral Muscular Dystrophy (FSHD) over 48 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, France, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJul 2019
Enrollment StartAug 2019
Primary CompletionJan 2021
TodayJul 2026
First PostedJul 1, 2019
Enrollment StartAug 9, 2019
Primary CompletionJan 28, 2021
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 7.0 years ago
Interventions
Losmapimod oral tabletdrug
Losmapimod will be administered with food when possible.
Placebo oral tabletdrug
Placebo will be administered with food when possible